Dahlia Biosciences
Enabling RNA Flow
San Francisco, United States · Founded 2017
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2017
- Business Model
- B2B
- Website
- dahliabio.com
- Last Round
- Convertible NoteJun 2019
- Rounds
- 1
About
Dahlia Biosciences develops RNA Flow Assays that enable ultra-throughput single-cell gene expression analysis, advancing research into inflammatory and other diseases.
Summary
Dahlia Biosciences is a Biotech company based in San Francisco, United States, founded in 2017. Its most recent funding was a Convertible Note round in Jun 2019. Investors include SOSV and IndieBio.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2019
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...